Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy

Svaton, Martin; Blazek, Jiri; Krakorova, Gabriela; Buresova, Marcela; Teufelova, Zuzana; Vodicka, Josef; Hurdalkova, Karolina; Barinova, Magda; Pesek, Milos

doi:10.7150/jca.58851



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(19):5753-5759. doi:10.7150/jca.58851 This issue Cite

Research Paper

Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy

Martin Svaton^1✉, Jiri Blazek¹, Gabriela Krakorova¹, Marcela Buresova¹, Zuzana Teufelova¹, Josef Vodicka², Karolina Hurdalkova³, Magda Barinova³, Milos Pesek¹

1. Department of Pneumology and Phthisiology, University hospital in Pilsen, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
2. Department of Surgery, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
3. Institute of Biostatistics and Analyses, Ltd. Brno, Czech Republic

Citation:

Svaton M, Blazek J, Krakorova G, Buresova M, Teufelova Z, Vodicka J, Hurdalkova K, Barinova M, Pesek M. Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. J Cancer 2021; 12(19):5753-5759. doi:10.7150/jca.58851. https://www.jcancer.org/v12p5753.htm

Other styles

Abstract

Purpose: To investigate potential associations between selected laboratory markers (CRP, LDH, albumin, sodium, hemoglobin, neutrophils, and neutrophils/lymphocytes ratio [NLR]) and outcomes in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab (BEV) plus chemotherapy.

Patients and Methods: We retrospectively analyzed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with BEV + chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis.

Results: We showed significantly better disease control rate when CRP, albumin, hemoglobin, and NLR were within established “normal” values. In univariate analysis, normal values of CRP, LDH, albumin, sodium, hemoglobin, neutrophils, and NLR were associated with better overall survival (OS). Normal values of CRP, albumin, hemoglobin, neutrophils, and NLR were associated also with better progression-free survival (PFS). In a multivariate Cox model, normal values of LDH, albumin, and NLR were associated with significantly better OS while normal CRP, albumin, and NLR were associated with better PFS.

Conclusions: LDH and sodium appear to be possible prognostic markers for BEV treatment in combination with chemotherapy in NSCLC. The parameters associated with inflammatory response (CRP, NLR, albumin, and possibly hemoglobin) appear to be promising predictive markers for this treatment combination.

Keywords: bevacizumab, inflammation, CRP, albumin, NSCLC, predictive, prognostic

Citation styles

APA

Svaton, M., Blazek, J., Krakorova, G., Buresova, M., Teufelova, Z., Vodicka, J., Hurdalkova, K., Barinova, M., Pesek, M. (2021). Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. Journal of Cancer, 12(19), 5753-5759. https://doi.org/10.7150/jca.58851.

ACS

Svaton, M.; Blazek, J.; Krakorova, G.; Buresova, M.; Teufelova, Z.; Vodicka, J.; Hurdalkova, K.; Barinova, M.; Pesek, M. Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. J. Cancer 2021, 12 (19), 5753-5759. DOI: 10.7150/jca.58851.

NLM

CSE

Svaton M, Blazek J, Krakorova G, Buresova M, Teufelova Z, Vodicka J, Hurdalkova K, Barinova M, Pesek M. 2021. Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. J Cancer. 12(19):5753-5759.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.